More on GRF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.37 |
|
|||
| Open | $10.37 | ||||
| 52 Wk High | $21.75 | ||||
| 52 Wk Low | $6.41 | ||||
| Day High | $10.37 | ||||
| Day Low | $10.37 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 246 | ||||
- Grifols starts two Phase 3 trials to expand immunoglobulin labels
- Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
- Grifols launches FESILTY fibrinogen concentrate in the US
- Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
- Form 4 EAGLE CAPITAL GROWTH For: May 22 Filed by: Sims David C
- Form 4 EAGLE CAPITAL GROWTH For: May 18 Filed by: SIMS LUKE E
- Form 6-K Grifols SA For: May 15
- Form SCHEDULE 13G/A Grifols SA Filed by: BRANDES INVESTMENT PARTNERS, LP
- Form 4 EAGLE CAPITAL GROWTH For: May 05 Filed by: Tyler Donald G
- Form 6-K Grifols SA For: May 07
Entities mentioned with GRF
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- 13G | View Related Stories »
- Nomura | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Deutsche Bank | View Related Stories »
- Show More...
